Ex-527 inhibits Sirtuins by exploiting their unique NAD+-dependent deacetylation mechanism

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 30, 2013, Pages

  Gertz, Melanie ^a   Fischer, Frank ^a   Nguyen, Giang Thi Tuyet ^a   Lakshminarasimhan, Mahadevan ^a   Schutkowski, Mike ^b   Weyand, Michael ^a   Steegborn, Clemens ^a  

^a UNIVERSITY OF BAYREUTH   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHORO 2,3,4,9 TETRAHYDRO 1H CARBAZOLE 1 CARBOXAMIDE; ADENOSINE DIPHOSPHATE RIBOSE ACETATE; CARBAZOLE DERIVATIVE; EX 527; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; SIRTUIN; SIRTUIN 1; SIRTUIN 3; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DEACETYLATION; DRUG BINDING; ELECTRON; ENANTIOMER; ENZYME CONFORMATION; HYDROLYSIS; KINETICS; NONHUMAN; PRIORITY JOURNAL; THERMOTOGA MARITIMA;

ACETYLATION; CARBAZOLES; MODELS, MOLECULAR; NAD; SIRTUINS; STEREOISOMERISM;

EID: 84880681461     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1303628110     Document Type: Article

References (57)

1. Michan S, Sinclair D (2007) Sirtuins in mammals: Insights into their biological function. Biochem J 404(1):1-13.
2. Haigis MC, Sinclair DA (2010) Mammalian sirtuins: Biological insights and disease relevance. Annu Rev Pathol 5:253-295.
3. Sauve AA, Wolberger C, Schramm VL, Boeke JD (2006) The biochemistry of sirtuins. Annu Rev Biochem 75:435-465.
4. Gertz M, Steegborn C (2010) Function and regulation of the mitochondrial sirtuin isoform Sirt5 in Mammalia. Biochim Biophys Acta 1804(8):1658-1665.
5. Bell EL, Guarente L (2011) The SirT3 divining rod points to oxidative stress. Mol Cell 42(5):561-568.
6. Lakshminarasimhan M, Steegborn C (2011) Emerging mitochondrial signaling mechanisms in physiology, aging processes, and as drug targets. Exp Gerontol 46(2-3):174-177.
7. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E (2003) The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 11(2):437-444.
8. Black JC, Mosley A, Kitada T, Washburn M, Carey M (2008) The SIRT2 deacetylase regulates autoacetylation of p300. Mol Cell 32(3):449-455.
9. Sanders BD, Jackson B, Marmorstein R (2010) Structural basis for sirtuin function: What we know and what we don't. Biochim Biophys Acta 1804(8):1604-1616.
10. Moniot S, Weyand M, Steegborn C (2012) Structures, substrates, and regulators of Mammalian sirtuins-opportunities and challenges for drug development. Front Pharmacol 3:16.
11. Cosgrove MS, et al. (2006) The structural basis of sirtuin substrate affinity. Biochemistry 45(24):7511-7521.
12. Gertz M, et al. (2012) A molecular mechanism for direct sirtuin activation by resveratrol. PLoS ONE 7(11):e49761.
13. Jin L, et al. (2009) Crystal structures of human SIRT3 displaying substrate-induced conformational changes. J Biol Chem 284(36):24394-24405.
14. Zhao K, Chai X, Marmorstein R (2003) Structure of the yeast Hst2 protein deacetylase in ternary complex with 2'-O-acetyl ADP ribose and histone peptide. Structure 11(11): 1403-1411.
15. Sauve AA (2010) Sirtuin chemical mechanisms. Biochim Biophys Acta 1804(8): 1591-1603.
16. Hoff KG, Avalos JL, Sens K, Wolberger C (2006) Insights into the sirtuin mechanism from ternary complexes containing NAD+ and acetylated peptide. Structure 14(8):1231-1240.
17. Chang JH, et al. (2002) Structural basis for the NAD-dependent deacetylase mechanism of Sir2. J Biol Chem 277(37):34489-34498.
18. Outeiro TF, et al. (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317(5837):516-519.
19. Sanchez-Fidalgo S, Villegas I, Sanchez-Hidalgo M, de la Lastra CA (2012) Sirtuin modulators: Mechanisms and potential clinical implications. Curr Med Chem 19(15): 2414-2441.
20. Lavu S, Boss O, Elliott PJ, Lambert PD (2008) Sirtuins-novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov 7(10):841-853.
21. Cen Y (2010) Sirtuins inhibitors: The approach to affinity and selectivity. Biochim Biophys Acta 1804(8):1635-1644.
22. Neugebauer RC, Sippl W, Jung M (2008) Inhibitors of NAD+ dependent histone deacetylases (sirtuins). Curr Pharm Des 14(6):562-573.
23. Mai A, et al. (2005) Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J Med Chem 48(24):7789-7795.
24. Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL (2001) Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem 276(42):38837-38843.
25. Suenkel B, Fischer F, Steegborn C (2013) Inhibition of the human deacylase Sirtuin 5 by the indole GW5074. Bioorg Med Chem Lett 23(1):143-146.
26. Chen L (2011) Medicinal chemistry of sirtuin inhibitors. Curr Med Chem 18(13): 1936-1946.
27. Napper AD, et al. (2005) Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem 48(25):8045-8054.
28. Solomon JM, et al. (2006) Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol 26(1):28-38.
29. Zhao X, et al. (2013) The 2.5 A crystal structure of the SIRT1 catalytic domain bound to nicotinamide adenine dinucleotide (NAD+) and an indole (EX527 analogue) reveals a novel mechanism of histone deacetylase inhibition. J Med Chem 56(3):963-969.
30. Kaeberlein M, et al. (2005) Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 280(17):17038-17045.
31. Smith BC, Hallows WC, Denu JM (2009) A continuous microplate assay for sirtuins and nicotinamide-producing enzymes. Anal Biochem 394(1):101-109.
32. Du J, et al. (2011) Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 334(6057):806-809.
33. Avalos JL, Bever KM, Wolberger C (2005) Mechanism of sirtuin inhibition by nicotinamide: Altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. Mol Cell 17(6):855-868.
34. Trapp J, et al. (2006) Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J Med Chem 49(25):7307-7316.
35. Hawse WF, et al. (2008) Structural insights into intermediate steps in the Sir2 deacetylation reaction. Structure 16(9):1368-1377.
36. Fischer F, et al. (2012) Sirt5 deacylation activities show differential sensitivities to nicotinamide inhibition. PLoS ONE 7(9):e45098.
37. Borra MT, Langer MR, Slama JT, Denu JM (2004) Substrate specificity and kinetic mechanism of the Sir2 family of NAD+-dependent histone/protein deacetylases. Biochemistry 43(30):9877-9887.
38. Stein RL (2011) Kinetics of Enzyme Action (Wiley, New York).
39. Blum CA, et al. (2011) SIRT1 modulation as a novel approach to the treatment of diseases of aging. J Med Chem 54(2):417-432.
40. Suzuki T, et al. (2009) Design, synthesis, enzyme inhibition, and tumor cell growth inhibition of 2-anilinobenzamide derivatives as SIRT1 inhibitors. Bioorg Med Chem 17(16):5900-5905.
41. Mai A, et al. (2009) Study of 1,4-dihydropyridine structural scaffold: Discovery of novel sirtuin activators and inhibitors. J Med Chem 52(17):5496-5504.
42. Jin L, et al. (2009) Biochemical characterization, localization, and tissue distribution of the longer form of mouse SIRT3. Protein Sci 18(3):514-525.
43. Avalos JL, Boeke JD, Wolberger C (2004) Structural basis for the mechanism and regulation of Sir2 enzymes. Mol Cell 13(5):639-648.
44. Szczepankiewicz BG, Koppetsch KJ, Perni RB (2011) One-step, nonenzymatic synthesis of O-acetyl-ADP-ribose and analogues from NAD and carboxylates. J Org Chem 76(16):6465-6474.
45. Lakshminarasimhan M, Rauh D, Schutkowski M, Steegborn C (2013) Sirt1 activation by resveratrol is substrate sequence-selective. Aging (Albany NY) 5(3):151-154.
46. Schlicker C, et al. (2008) Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5. J Mol Biol 382(3):790-801.
47. Mueller U, et al. (2012) Facilities for macromolecular crystallography at the Helmholtz-Zentrum Berlin. J Synchrotron Radiat 19(Pt 3):442-449.
48. Kabsch W (2010) Xds. Acta Crystallogr D Biol Crystallogr 66(Pt 2):125-132.
49. McCoy AJ, et al. (2007) Phaser crystallographic software. J Appl Cryst 40(Pt 4): 658-674.
50. Vagin AA, Isupov MN (2001) Spherically averaged phased translation function and its application to the search for molecules and fragments in electron-density maps. Acta Crystallogr D Biol Crystallogr 57(Pt 10):1451-1456.
51. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihoodmethod. Acta Crystallogr D Biol Crystallogr 53(Pt 3):240-255.
52. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60(Pt 12 Pt 1):2126-2132.
53. Brünger AT (1992) Free R value: A novel statistical quantity for assessing the accuracy of crystal structures. Nature 355(6359):472-475.
54. Schüttelkopf AW, van Aalten DM (2004) PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60(Pt 8): 1355-1363.
55. Chen VB, et al. (2010) MolProbity: All-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66(Pt 1):12-21.
56. Wienken CJ, Baaske P, Rothbauer U, Braun D, Duhr S (2010) Protein-binding assays in biological liquids using microscale thermophoresis. Nat Commun 1:100.
57. Zhou Y, et al. (2012) The bicyclic intermediate structure provides insights into the desuccinylation mechanismof human sirtuin 5 (SIRT5). J BiolChem287(34):28307-28314.